

Doctor's Note — Clinical Trial Summary

Generated by FindMyCure.ai on April 2, 2026 | For discussion with your oncologist

TRIAL

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

NCT ID: NCT06007690 Phase: PHASE3 Sponsor: Aura Biosciences Status: Recruiting

SUMMARY

The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).

KEY ELIGIBILITY CRITERIA

- * Clinical diagnosis of primary indeterminate lesion or small choroidal melanoma (IL/CM)
- * Have no evidence of metastatic disease confirmed by imaging
- * Be treatment naive for IL/CM (subjects who received PDT may be eligible)
- * Have known contraindications or sensitivities to the study drug or laser
- * Active ocular infection or disease

Total sites: 71 | 68 currently recruiting